PR Newswire PharmaOriginal article
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
Phase 2positiveASC50Positive
AI Analysis
Summary
Ascletis announced positive Phase 2 proof-of-concept results for ASC50, a first-in-class and best-in-class oral IL-17A inhibitor, achieving 48.9% placebo-adjusted reduction in PASI scores in mild-to-moderate plaque psoriasis patients at once-daily 200 mg dosing with favorable pharmacokinetics.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
48.9% placebo-adjusted reduction in PASI score in mild-to-moderate plaque psoriasis patients with once-daily 200 mg treatment over 28 days; steady-state elimination half-life of 6.5 days
Importance:6/10
Sentiment:
0.75
clinical_trialdermatologypositive_dataIL-17A_inhibitororal_small_molecule
Read the original article
Published by PR Newswire Pharma on September 29, 2026 12:00 AM